Unlock instant, AI-driven research and patent intelligence for your innovation.
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
a technology of genes and proteins, applied in the direction of peptide/protein ingredients, fusion polypeptides, chemical treatment enzyme inactivation, etc., can solve the problem that the complexity of biological systems overwhelmed the ability of practitioners to understand the molecular interactions
Inactive Publication Date: 2012-02-23
MILLENNIUM PHARMA INC
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0044]INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof exhibit the ability to affect growth, proliferation, survival, differentiation, and activity of human pancreas, skeletal muscle, heart, brain, placenta, lung, liver, and kidney cells. INTERCEPT 217 modulates cellular binding to one or more mediators, modulates activity and release of one or more pancreatically secreted digestive enzymes, and protects tissue from endogenous digestive enzymes. INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, or treat disorders relating to aberrant endogenous digestive enzyme activity, inappropriate interaction (or non-interaction) of cells with mediators, inappropriate cellular development and proliferation, inappropriate inflammation, and inappropriate immune responses.
[0047]TANGO 292 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human keratinocytes, including embryonic keratinocytes. TANGO 292, a transmembrane protein, is also involved in binding and uptake of calcium and other metal ions, and in responses of cells which express it to the presence and uptake of such ions. TANGO 292 polypeptides, nucleic acids, and modulators can be used to prevent, diagnose, and treat disorders involving one or more of bone uptake, maintenance, and deposition, formation, maintenance, and repair of cartilage and skin, formation and maintenance of extracellular matrices, movement of cells through extracellular matrices, coagulation and dissolution of blood components, and deposition of materials in and on arterial walls.
Problems solved by technology
In the past, the complexity of biological systems overwhelmed the ability of practitioners to understand the molecular interactions giving rise to normal and abnormal physiological states.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0110]The present invention is based, at least in part, on the discovery of a variety of cDNA molecules which encode proteins which are herein designated TANGO 202, TANGO 210, INTERCEPT 217, TANGO 229, TANGO 234, TANGO 265, TANGO 276, TANGO 286, INTERCEPT 289, TANGO 292, TANGO 294, INTERCEPT 296, INTERCEPT 297, INTERCEPT 309, TANGO 331, TANGO 332, TANGO 366, INTERCEPT 394, INTERCEPT 400, TANGO 416, MANGO 419, INTERCEPT 429, and TANGO 457. These proteins exhibit a variety of physiological activities, and are included in a single application for the sake of convenience. It is understood that the allowability or non-allowability of claims directed to one of these proteins has no bearing on the allowability of claims directed to the others. The characteristics of each of these proteins and the cDNAs encoding them are described separately in the ensuing sections. In addition to the full length mature and immature proteins described in the following sections, the invention includes fragme...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
length
aaaaa
aaaaa
nucleic acid
aaaaa
aaaaa
nucleic acid sequences
aaaaa
aaaaa
Login to View More
Abstract
The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 12 / 387,959, filed on May 8, 2009 (published), which is a continuation of U.S. application Ser. No. 10 / 741,790, filed on Dec. 19, 2003 (now U.S. Pat. No. 7,547,766), which is a continuation of U.S. application Ser. No. 09 / 759,130, filed Jan. 12, 2001 (now abandoned).[0002]U.S. application Ser. No. 09 / 759,130, is a continuation-in-part of U.S. application Ser. No. 09 / 479,249, filed on Jan. 7, 2000 (abandoned), and a continuation-in-part of U.S. application Ser. No. 09 / 559,497, filed on Apr. 27, 2000 (abandoned).[0003]U.S. application Ser. No. 09 / 759,130, is also a continuation-in-part of U.S. application Ser. No. 09 / 578,063, filed on May 24, 2000 (now U.S. Pat. No. 6,764,677), which is a continuation-in-part of U.S. application Ser. No. 09 / 333,159, filed on Jun. 14, 1999 (now U.S. Pat. No. 7,033,780).[0004]U.S. application Ser. No. 09 / 759,130, is also a continuation-in-part of ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More
Patent Type & Authority Applications(United States)
Inventor FRASER, CHRISTOPHER C.BARNES, THOMAS M.SHARP, JOHN D.KIRST, SUSAN J.MYERS, PAUL S.LEIBY, KEVIN R.HOLTZMAN, DOUGLAS A.MCCARTHY, SEAN A.WRIGHTON, NICHOLASMACKAY, CHARLES R.GOODEARL, ANDREW D.J.